(2-methoxyphenyl)-[2,3-dichloro-4(E-[(4-carboxypiperidin-1-yl)carbonyl]ethenyl)phenyl]sulfide | 280751-81-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (2-methoxyphenyl)-[2,3-dichloro-4(E-[(4-carboxypiperidin-1-yl)carbonyl]ethenyl)phenyl]sulfide
• 英文别名: (E)-1-(3-(2,3-dichloro-4-(2-methoxyphenylthio)phenyl)acryloyl)piperidine-4-carboxylic acid；1-{3-[2,3-Dichloro-4-(2-methoxy-phenylsulfanyl)-phenyl]-acryloyl}-piperidine-4-carboxylic acid；1-[(E)-3-[2,3-dichloro-4-(2-methoxyphenyl)sulfanylphenyl]prop-2-enoyl]piperidine-4-carboxylic acid
• CAS: 280751-81-7
• 化学式: C₂₂H₂₁Cl₂NO₄S
• 分子量: 466.385
• InChiKey: QPWDZBBZIVDASP-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  92.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2-methoxyphenyl)-[2,3-dichloro-4(E-[(4-carboxypiperidin-1-yl)carbonyl]ethenyl)phenyl]sulfide 在 N,N-二甲基甲酰胺 、 4-二甲氨基吡啶 草酰氯 、 O-(三甲基硅)羟胺 、 N,N-二异丙基乙胺 、 四丁基氟化铵 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 4.0h， 生成 (2-Methoxyphenyl)[2,3-dichloro-4-(E-(((4-hydroxylaminocarbonyl)piperidin-1-yl)carbonyl)ethenyl)phenyl]sulfide
  参考文献：
  名称：

  Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

  摘要：

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。

  公开号：

  US20040116518A1
• 作为产物：
  描述：

  2,3-二氯-4-羟基苯甲醛 在 哌啶 、 吡啶 、 sodium hydroxide 、 草酰氯 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 甲苯 、 乙腈 、 苯 为溶剂， 反应 6.3h， 生成 (2-methoxyphenyl)-[2,3-dichloro-4(E-[(4-carboxypiperidin-1-yl)carbonyl]ethenyl)phenyl]sulfide
  参考文献：
  名称：

  Discovery of Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 4. Structure−Activity Relationship of Substituents on the Benzene Ring of the Cinnamide

  摘要：

  We have shown that p-arylthio cinnamides can inhibit the interaction of LFA-1 and ICAM-1, which is involved in cell adhesion and the inflammatory process. We now show that 2,3-disubstitution on the aryl portion of the cinnamide results in enhanced activity over mono substitution on the ring. The best 2,3-substituents were chlorine and trifluoromethyl groups. Compounds 39 and 40 which contain two CF3 groups have IC50 values of 0.5 and 0.1 nM, respectively, in inhibiting JY8 cells expressing LFA-1 on their surface, from adhering to ICAM-1. The structure-activity relationship (SAR) was examined using an NMR based model of the LFA-1 I domain/compound 31 complex. One of our compounds (38) was able to reduce cell migration in two different in vivo experiments.

  DOI：

  10.1021/jm0103108

文献信息

• INHIBITORS OF VIRAL REPLICATION
  申请人：Beigelman Leonid

  公开号：US20090099186A1

  公开（公告）日：2009-04-16

  The embodiments provide compounds of the general Formulas I-IV, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  实施例提供了一般公式I-IV的化合物，以及包括主题化合物的组合物，包括药物组合物。实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用主题化合物或组合物的有效量。
• [EN] INHIBITORS OF VIRAL REPLICATION<br/>[FR] INHIBITEURS DE RÉPLICATION VIRALE
  申请人：INTERMUNE INC

  公开号：WO2007047146A2

  公开（公告）日：2007-04-26

  [EN] The embodiments provide compounds of the general Formulas I-IV, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
  [FR] Les modes de réalisation de l'invention concernent des composés de formules générales I-IV, ainsi que des compositions, y compris des compositions pharmaceutiques, qui comprennent un composé objet de l'invention. Les modes de réalisation concernent en outre des méthodes de traitement, y compris des méthodes pour traiter une infection virale d'hépatite C et des méthodes pour traiter une fibrose hépatique ; lesdites méthodes impliquent généralement l'administration d'une quantité efficace d'un composé ou d'une composition objet de l'invention à un individu qui en a besoin.
• Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：US20040116518A1

  公开（公告）日：2004-06-17

  The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。
• Discovery of Novel <i>p</i>-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 4. Structure−Activity Relationship of Substituents on the Benzene Ring of the Cinnamide
  作者：Martin Winn、Edward B. Reilly、Gang Liu、Jeffrey R. Huth、Hwan-Soo Jae、Jennifer Freeman、Zhonghua Pei、Zhili Xin、John Lynch、Jeff Kester、Thomas W. von Geldern、Sandra Leitza、Peter DeVries、Robert Dickinson、Donna Mussatto、Gregory F. Okasinski

  DOI：10.1021/jm0103108

  日期：2001.12.1

  We have shown that p-arylthio cinnamides can inhibit the interaction of LFA-1 and ICAM-1, which is involved in cell adhesion and the inflammatory process. We now show that 2,3-disubstitution on the aryl portion of the cinnamide results in enhanced activity over mono substitution on the ring. The best 2,3-substituents were chlorine and trifluoromethyl groups. Compounds 39 and 40 which contain two CF3 groups have IC50 values of 0.5 and 0.1 nM, respectively, in inhibiting JY8 cells expressing LFA-1 on their surface, from adhering to ICAM-1. The structure-activity relationship (SAR) was examined using an NMR based model of the LFA-1 I domain/compound 31 complex. One of our compounds (38) was able to reduce cell migration in two different in vivo experiments.